BLI (Biolayer interferometry) binding affinity measurements of MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) to Mosunetuzumab and Cevostamab.
Mosunetuzumab captured on HFC (Anti-Human IgG Fc) Probes can bind MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit with a dissociation constant (KD) of 2.37E-09M.
Cevostamab captured on HFC (Anti-Human IgG Fc) Probes can bind MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit with a dissociation constant (KD) of 9.48E-10M.

Left Figure: Anti-Mosunetuzumab Antibodies inhibit the binding of Mosunetuzumab to Human CD3 Epsilon. Coating antigen: Mosunetuzumab, 1 µg/mL.
Human CD3 Epsilon final concentration: 12.5 ng/mL.
Anti-Mosunetuzumab antibody dilutions start from 30 μg/mL.
MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) exhibited non-inhibitory properties, whereas both MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) demonstrated significant inhibitory properties.

Right Figure: Anti-Mosunetuzumab Antibodies inhibit the binding of Cevostamab to Human CD3 Epsilon. Coating antigen: Cevostamab, 1 µg/mL.
Human CD3 Epsilon final concentration: 7 ng/mL.
Anti-Mosunetuzumab antibody dilutions start from 30 μg/mL.
MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) exhibited non-inhibitory properties, whereas both MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) demonstrated significant inhibitory properties.

Left Figure: Standard Curve of Mosunetuzumab Sandwich ELISA by A02292 (10D5) and Anti-Human IgG Fc Antibody
In this Sandwich ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) was coated at a concentration of 1 μg/mL, and Mouse Anti-Human IgG Fc Antibody (50B4A9)[HRP], mAb (GenScript, A01854) as a detection antibody at a concentration of 0.2 μg/mL. MRD was as 1:5.
In this assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square equal to 0.99993. The typicaldynamic range of the assay is 10 - 650 ng/mL. Right Figure: Standard Curve of Cevostamab Sandwich ELISA by A02292 (10D5) and Anti-Human IgG Fc Antibody
In this Sandwich ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) was coated at a concentration of 1 μg/mL, and Mouse Anti-Human IgG Fc Antibody (50B4A9)[HRP], mAb (GenScript, A01854) as a detection antibody at a concentration of 0.2 μg/mL. MRD was as 1:5.
In this assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square equal to 0.999. The typicaldynamic range of the assay is 2 - 150 ng/mL.

MRD Analysis of the Detection of Mosunetuzumab or Cevostamab in Biological Matrix.
The MRD is the minimum dilution necessary for the detection of Mosunetuzumab or Cevostamab in biological matrix with least interference. Serum samples from cynomolgus monkey were serially diluted to determine the MRD of this assay, and the test result suggested that MRD was as 1:5.
In this Sandwich ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) was coated at a concentration of 1 μg/mL, and Mouse Anti-Human IgG Fc Antibody (50B4A9)[HRP], mAb (GenScript, A01854) as a detection antibody at a concentration of 0.2 μg/mL.